8-K: Verastem Oncology Eyes Mid-2025 Launch for Novel RAS/MAPK Therapy in LGSOC

Verastem Oncology is preparing for a mid-2025 launch of avutometinib and defactinib as a potential first FDA-approved treatment for KRAS mutant recurrent Low-Grade Serous Ovarian Cancer (LGSOC).

Summary

• Verastem Oncology is focused on developing therapies for RAS/MAPK-driven cancers.
• The company anticipates a mid-2025 launch of avutometinib and defactinib for KRAS mutant recurrent LGSOC, with a PDUFA date of June 30, 2025.
• A discovery partnership with GenFleet Therapeutics is underway for novel RAS pathway-related programs, including a KRAS G12D inhibitor.
• Market expansion opportunities are being explored with avutometinib + defactinib in first-line metastatic pancreatic cancer and advanced lung cancer.
• The company is pursuing a lean and focused field team for the launch, targeting high market penetration in KRAS mutant recurrent LGSOC.
• 70% of LGSOC tumors are driven by RAS/MAPK pathway-associated mutations, with 30% being KRAS mutant.
• Avutometinib is an oral RAF/MEK clamp, and defactinib is an oral selective FAK inhibitor, aiming for a more complete blockade of signaling that drives tumor growth.
• The RAMP 301 trial aims to complete enrollment by the end of 2025.
• The company plans to present additional data from the RAMP 205 trial in mid-year 2025.
• Verastem filed a U.S. IND for VS-7375 in Q1 2025 and plans to initiate a Phase 1/2a study in mid-2025.
• The company had $88.8M in cash, cash equivalents, and short-term investments as of December 31, 2024, with a pro forma balance of $151.3M after accounting for recent financing activities.
• Q4 2024 non-GAAP operating expenses were $29.6M.
• The company has an Oberland Finance credit facility with up to $150M available.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Verastem, highlighting the potential approval and commercialization of avutometinib and defactinib, ongoing clinical trials, and collaborations. The financial position is also presented favorably with recent financing activities.

Positives

• Potential to bring avutometinib and defactinib combo as the first and only FDA approved treatment for KRAS mutant recurrent LGSOC in 2025.
• Clear regulatory path for KRAS Mutant under the Accelerated Approval pathway received Priority Review and June 30, 2025 PDUFA Action Date for KRAS mutant recurrent LGSOC.
• RAMP 301 enrollment remains on track and will continue enrolling all comers.
• The company is committed to make the combination available to patients with KRAS wild-type in several ways, including a path for regulatory approval.
• Significant Market Opportunity in Area of High Unmet Need.
• The company plans to be launch ready in first-half of 2025 to maximize market opportunity in KRAS mutant recurrent LGSOC.
• The company plans to submit for NCCN guideline inclusion upon FDA approval.
• The company has a lean and focused field team for access, scientific exchange, and sales.
• The company has surround sound support programs for HCO/KEY ACCOUNTS, PATIENTS, and GPO.

Negatives

• The combination of Avutometinib and Defactinib is an investigational drug and has not been proven to be safe or effective and has not been approved by FDA or any other comparable regulatory authority.
• Current SoC (Chemo/Hormonal) is associated with low response rates (6 13%) with PFS below 12 months and high discontinuation rates due to toxicity.

Risks

• The success in the development and potential commercialization of our product candidates, including avutometinib in combination with other compounds, including defactinib, LUMAKRAS and others.
• The uncertainties inherent in research and development, such as negative or unexpected results of clinical trials, the occurrence or timing of applications for our product candidates that may be filed with regulatory authorities in any jurisdictions.
• Whether and when regulatory authorities in any jurisdictions may approve any such applications that may be filed for our product candidates, and, if approved, whether our product candidates will be commercially successful in such jurisdictions.
• Our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates.
• The scope, timing, and outcome of any legal proceedings.
• Decisions by regulatory authorities regarding trial design, labeling and other matters that could affect the timing, availability or commercial potential of our product candidates.
• Whether preclinical testing of our product candidates and preliminary or interim data from clinical trials will be predictive of the results or success of ongoing or later clinical trials.
• That the timing, scope and rate of reimbursement for our product candidates is uncertain.
• That the market opportunities of our drug candidates are based on internal and third-party estimates which may prove to be incorrect.
• That third-party payors (including government agencies) may not reimburse.
• That there may be competitive developments affecting our product candidates.
• That data may not be available when expected.
• That enrollment of clinical trials may take longer than expected, which may delay our development programs, including delays in review by the FDA of our NDA submission in recurrent KRAS mutant LGSOC if enrollment in our confirmatory trial is not well underway at the time of submission or that the FDA may require the Company to have completed enrollment or to enroll additional patients in the Company's ongoing RAMP 301 confirmatory Phase 3 clinical trial prior to the FDA taking action on our NDA under the accelerated approval pathway.
• Risks associated with preliminary and interim data, which may not be representative of more mature data, including with respect to interim duration of therapy data.
• That our product candidates will cause adverse safety events and/or unexpected concerns may arise from additional data or analysis, or result in unmanageable safety profiles as compared to their levels of efficacy.
• That we may be unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so.
• That the mature RAMP 201 data and associated discussions with the FDA may not support the scope of our NDA submission for the avutometinib and defactinib combination in LGSOC, including with respect to KRAS wild type LGSOC.
• That our product candidates may experience manufacturing or supply interruptions or failures.
• That any of our third-party contract research organizations, contract manufacturing organizations, clinical sites, or contractors, among others, who we rely on fail to fully perform.
• That we face substantial competition, which may result in others developing or commercializing products before or more successfully than we do which could result in reduced market share or market potential for our product candidates.
• That we will be unable to successfully initiate or complete the clinical development and eventual commercialization of our product candidates.
• That the development and commercialization of our product candidates will take longer or cost more than planned, including as a result of conducting additional studies or our decisions regarding execution of such commercialization.
• That we may not have sufficient cash to fund our contemplated operations, including certain of our product development programs.
• That we may not attract and retain high quality personnel.
• That we or Chugai Pharmaceutical Co., Ltd. will fail to fully perform under the avutometinib license agreement.
• That our total addressable and target markets for our product candidates might be smaller than we are presently estimating.
• That we or Secura Bio, Inc. will fail to fully perform under the asset purchase agreement with Secura Bio, Inc., including in relation to milestone payments.
• That we will not see a return on investment on the payments we have and may continue to make pursuant to the collaboration and option agreement with GenFleet, or that GenFleet will fail to fully perform under the agreement.
• That we may not be able to establish new or expand on existing collaborations or partnerships, including with respect to in-licensing of our product candidates, on favorable terms, or at all.
• That we may be unable to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity, debt financing or otherwise.
• That we will not pursue or submit regulatory filings for our product candidates.
• That our product candidates may not receive regulatory approval, become commercially successful products, or result in new treatment options being offered to patients.

Future Outlook

Verastem anticipates a near-term commercial launch of avutometinib and defactinib in LGSOC, followed by potential expansion into larger patient populations with pancreatic and lung cancer. The company also expects to share updated preclinical and clinical data at medical meetings in H1 2025.

Industry Context

The document highlights Verastem's focus on RAS/MAPK pathway-driven cancers, a significant area of research and development in oncology. The company's lead asset, avutometinib, is being developed in combination with defactinib to address the unmet need in KRAS mutant LGSOC, a rare and difficult-to-treat cancer. The collaboration with GenFleet Therapeutics expands Verastem's pipeline with novel RAS pathway-related programs, including a KRAS G12D inhibitor, which could potentially address a broader range of cancers.

Comparison to Industry Standards

• Current treatments for recurrent LGSOC, such as chemotherapy and hormonal therapy, offer poor to moderate response rates (6-13%) and progression-free survival (PFS) below 12 months, with high discontinuation rates due to toxicity.
• Trametinib, another treatment option, has a 26% ORR based on INV assessment of comparator arm of all patients not BICR and a 36% discontinuation rate due to AEs based on GOG 281.
• Binimetinib had a 16% ORR based on BICR of comparator arm and 31% discontinuation rate due to AEs based on MILO study.
• The avutometinib + defactinib combination has shown clinically meaningful response rates and durable benefit in both KRAS mutant and wild-type tumors in the RAMP 201 study.
• In first-line metastatic pancreatic cancer, standard of care treatments like Gem/NabP have ORRs between 23% 36% and median overall survival between 8.5 9.2 months.
• Nalirifox has shown an ORR of 41.8% and median overall survival of 11.1 months in first-line metastatic pancreatic cancer.
• Folfirinox has shown an ORR of 31.6% and median overall survival of 11.1 months in first-line metastatic pancreatic cancer.

Stakeholder Impact

• Shareholders: Potential for increased value through successful drug development and commercialization.
• Patients: Access to a potential new treatment option for LGSOC and other cancers.
• Employees: Opportunity to contribute to the development and launch of innovative therapies.
• Partners: Collaboration opportunities with GenFleet Therapeutics and other organizations.

Next Steps

• Primary analysis from FRAME and RAMP 201 clinical trials anticipated to be published in H1 2025.
• Plan for FDA decision: June 30, 2025, PDUFA action date.
• Plan to submit for NCCN guideline inclusion upon FDA approval.
• Report initial data from the RAMP 201J Phase 2 clinical trial being conducted in Japan in H2 2025.
• Complete enrollment in RAMP 301 Phase 3 confirmatory study by end of 2025.
• Plan to present additional data at a medical meeting in mid-year 2025 from the RAMP 205 trial.
• Select RP2D for trial expansion in H1 2025 for the RAMP 205 trial.
• Present an interim update of both doublet and triplet data at a medical meeting in H2 2025 for the RAMP 203 trial.
• GenFleet plans to continue to enroll patients into Phase 2 trial for VS-7375/GFH375 in China in patients with KRAS G12D-mutated advanced solid tumors.
• Expect to initiate Phase 1/2a trial for VS-7375 in U.S. mid-2025.
• Verastem/GenFleet expect to share updated preclinical and clinical data at medical meetings in H1 2025.
• Ongoing discovery/lead optimization in second and third programs.

Key Dates

Keywords

Avutometinib, Defactinib, LGSOC, KRAS, RAS/MAPK, GenFleet, VS-7375, Oncology, Verastem, Therapeutics